Federal Budget: What it means for the CSL (ASX:CSL) share price

The Federal Budget has earmarked lots of cash for COVID-19 treatments. Here's why that's good news for the CSL Limited (ASX: CSL) share price.

The CSL Limited (ASX: CSL) share price has done well in 2020 and the Federal Budget could have more good news in store.

While the S&P/ASX 200 Index (ASX: XJO) has slumped 10.9% this year, the CSL share price has climbed 4.4% higher.

I think the Federal Budget contained good news for vaccines and those organisations involved with the push towards coronavirus treatments. This to me says the CSL share price could be on the move in the coming months.

CSL share price represented by hand in blue glove picks out a vial labelled 'covid-19 vaccine' from a row of vials

Image source: Getty Images

What the Federal Budget means for the CSL share price

There were a lot of areas covered by Treasurer Josh Frydenberg in last night's Federal Budget. One of those surrounded potential COVID-19 vaccine candidates such as that being developed by the University of Queensland 

CSL is partnering with the Aussie university as it researches a potential vaccination candidate. That's already seen the Aussie biotech ink a deal with the government to supply 84.8 million doses of any COVID-19 vaccine.

However, Treasurer Frydenberg has earmarked billions of dollars for spending on COVID-19 vaccines, both here and abroad. $1.7 billion is already being spent in agreements for the University of Oxford and the University of Queensland vaccines.

There's also more money going towards the CSIRO and the Medical Research Future Fund for more COVID-19 research.

I see more focus on healthcare and vaccine development as good news for the CSL share price. The more government support and goodwill towards the sector that exists, the better the operating environment for CSL.

Depending on the successful vaccine candidate(s), we could also see further deals signed with CSL depending on global and domestic demand.

Foolish takeaway

The CSL share price has already outperformed in 2020 but I think it has further to run. I think COVID-19 will continue to dominate share market movements in the next 6-12 months.

That means major partners like CSL may continue to hold their gains despite volatility in the market.

Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »